Review Article

A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan

Table 1

All eligible studies.

Study IDLocDiagnosisIBS-C of total patientsAge () of femalesInterventionTrial stageRef no.MA

Fukudo 2019Japan<3 SBMs per week, Rome III diagnostic criteria for functional constipationNot included18182.3%Linaclotide 0.5 mgIII7Included
Fukudo 2018Japan<3 SBMs per week, Rome III diagnostic criteria for functional constipationNot included38283.2%Linaclotide 0.0625 mg
Linaclotide 0.125 mg
Linaclotide 0.25 mg
Linaclotide 0.5 mg
II8Included
Kumagai 2018Japan<3 SBMs per week, Rome III diagnostic criteria for functional constipationIncluded58Not reportedElobixibat 2.5 mg
Elobixibat 5 mg
Elobixibat 10 mg
Elobixibat 15 mg
Elobixibat 20 mg
I9Included
Nakajima 2018aJapanRome III diagnostic criteria for functional constipationIncluded13282.6%Elobixibat 10 mgIII10Included
Nakajima 2018bJapanRome III diagnostic criteria for functional constipationIncluded16387.7%Elobixibat 5 mg
Elobixibat 10 mg
Elobixibat 15 mg
II11Included
Fukudo 2015Japan<3 SBMs per week, Rome III diagnostic criteria for functional constipationIncluded12487.9%Lubiprostone 48 mgIII6Included
Fukudo 2011Japan<3 SBMs per week, Rome III diagnostic criteria for functional constipationIncluded17090.6%Lubiprostone 16 μg
Lubiprostone 32 μg
Lubiprostone 48 μg
II5Included
Mori 2019JapanRome IV diagnostic criteria for functional constipationIncluded33100.0%Magnesium oxide21
Nakajima 2019Japan<3 SBMs per week, Rome III diagnostic criteria for functional constipationIncluded15685.6%Polyethylene glycol 3350 plus electrolytesIII17
Kasugai 2019Japan<3 SBMs per week, Rome III diagnostic criteria for functional constipationIncluded25084.0%Lactulose 13 g/day
Lactulose 26 g/day
Lactulose 39 g/day
II12Included

IBS-C: irritable bowel syndrome with constipation; Loc: location; MA: meta-analysis; : number; : proportion; Ref no.: reference number; SBM: spontaneous bowel movement.